DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Halofuginone is an investigational drug.
There have been 5 clinical trials for Halofuginone. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2003.
The most common disease conditions in clinical trials are Muscular Dystrophy, Duchenne, Muscular Dystrophies, and Sarcoma, Kaposi. The leading clinical trial sponsors are Akashi Therapeutics, National Cancer Institute (NCI), and European Organisation for Research and Treatment of Cancer - EORTC.
Recent Clinical Trials for Halofuginone
|HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02||Akashi Therapeutics||Phase 2|
|Open Label Extension Study of HT-100 in Patients With DMD||Akashi Therapeutics||Phase 2|
|Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy||Akashi Therapeutics||Phase 1/Phase 2|